- Home
- BCAB vs ATCH Comparison
BCAB vs ATCH Comparison
Compare BCAB & ATCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- ATCH
- Stock Information
- Founded
- BCAB 2007
- ATCH 2022
- Country
- BCAB United States
- ATCH United States
- Employees
- BCAB N/A
- ATCH N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- ATCH
- Sector
- BCAB Health Care
- ATCH
- Exchange
- BCAB Nasdaq
- ATCH Nasdaq
- Market Cap
- BCAB 40.5M
- ATCH 39.9M
- IPO Year
- BCAB 2020
- ATCH N/A
- Fundamental
- Price
- BCAB $0.78
- ATCH $0.31
- Analyst Decision
- BCAB Hold
- ATCH
- Analyst Count
- BCAB 3
- ATCH 0
- Target Price
- BCAB $1.00
- ATCH N/A
- AVG Volume (30 Days)
- BCAB 1.2M
- ATCH 17.6M
- Earning Date
- BCAB 11-13-2025
- ATCH 11-14-2025
- Dividend Yield
- BCAB N/A
- ATCH N/A
- EPS Growth
- BCAB N/A
- ATCH N/A
- EPS
- BCAB N/A
- ATCH N/A
- Revenue
- BCAB N/A
- ATCH $12,303,120.00
- Revenue This Year
- BCAB N/A
- ATCH N/A
- Revenue Next Year
- BCAB N/A
- ATCH N/A
- P/E Ratio
- BCAB N/A
- ATCH N/A
- Revenue Growth
- BCAB N/A
- ATCH 80.78
- 52 Week Low
- BCAB $0.24
- ATCH $0.14
- 52 Week High
- BCAB $2.05
- ATCH $18.33
- Technical
- Relative Strength Index (RSI)
- BCAB 55.58
- ATCH 42.23
- Support Level
- BCAB $0.62
- ATCH $0.30
- Resistance Level
- BCAB $0.73
- ATCH $0.36
- Average True Range (ATR)
- BCAB 0.09
- ATCH 0.04
- MACD
- BCAB 0.00
- ATCH -0.00
- Stochastic Oscillator
- BCAB 47.44
- ATCH 4.82
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.